GH001
Treatment-Resistant Depression (TRD)
Key Facts
About GH Research
GH Research is an Irish biotech company founded in 2018 with a mission to revolutionize the treatment of severe psychiatric disorders through its innovative mebufotenin-based platform. Its core achievement is the development of the Individualized Dosing Regimen (IDR), which has demonstrated high remission rates in early trials for treatment-resistant depression. The company's strategy is to advance its lead inhaled formulation, GH001, through late-stage clinical development for multiple indications, leveraging its strong intellectual property portfolio and aiming to address a massive unmet need with a potentially paradigm-shifting therapy.
View full company profileAbout GH Research
GH Research is an Irish biotech company founded in 2018 with a mission to revolutionize the treatment of severe psychiatric disorders through its innovative mebufotenin-based platform. Its core achievement is the development of the Individualized Dosing Regimen (IDR), which has demonstrated high remission rates in early trials for treatment-resistant depression. The company's strategy is to advance its lead inhaled formulation, GH001, through late-stage clinical development for multiple indications, leveraging its strong intellectual property portfolio and aiming to address a massive unmet need with a potentially paradigm-shifting therapy.
View full company profileAbout GH Research
GH Research is an Irish biotech company founded in 2018 with a mission to revolutionize the treatment of severe psychiatric disorders through its innovative mebufotenin-based platform. Its core achievement is the development of the Individualized Dosing Regimen (IDR), which has demonstrated high remission rates in early trials for treatment-resistant depression. The company's strategy is to advance its lead inhaled formulation, GH001, through late-stage clinical development for multiple indications, leveraging its strong intellectual property portfolio and aiming to address a massive unmet need with a potentially paradigm-shifting therapy.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression (TRD) Drugs
| Drug | Company | Phase |
|---|---|---|
| CYC-126 | Cyclerion Therapeutics | Phase 1 |
| DOT | Motif Neurotech | Pre-clinical |
| FMP374 | FundaMental Pharma | Preclinical |
| R-107 | Tasman Therapeutics | Phase 3 |
| COMP360 Psilocybin Therapy | Compass Pathways | Phase 3 |
| Ketamir-2 (Ketamir) | MIRA Pharmaceuticals | Phase 1 |